Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1999-03-26
2001-04-03
Schwartzman, Robert A. (Department: 1635)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S375000, C536S023100, C536S024300, C536S024500
Reexamination Certificate
active
06210892
ABSTRACT:
FIELD OF THE INVENTION
The present invention provides compositions and methods for controlling a cellular behavior by antisense modulation of messenger RNA (mRNA)processing. In particular, this invention relates to antisense compounds, particularly oligonucleotides, which modulate RNA splicing, polyadenylation, or stability in order to affect the behavior of a cell.
BACKGROUND OF THE INVENTION
Newly synthesized eukaryotic mRNA molecules, known as primary transcripts or pre-mRNA, made in the nucleus, are processed before or during transport to the cytoplasm for translation. A methylated cap structure, consisting of a terminal nucleotide, 7-methylguanylate, is added to the 5′ end of the mRNA in a 5′—5′ linkage with the first nucleotide of the mRNA sequence.
An approximately 200-250-base sequence of adenylate residues, referred to as poly(A), is added posttranscriptionally to a site that will become the 3′ terminus of the mRNA, before entry of the mRNA into the cytoplasm. This is a multistep process which involves assembly of a processing complex, then site-specific endonucleolytic cleavage of the precursor transcript, and addition of a poly(A) “tail.” In most mRNAs the polyadenylation signal sequence is a hexamer, AAUAAA, located 10 to 30 nucleotides in the 5′ direction (upstream) from the site of cleavage (5′-CA-3′) in combination with a U or G-U rich element 3′ to the cleavage site. Multiple poly(A) sites may be present on a given transcript, of which only one is used per transcript, but more than one species of mature mRNA transcript can be produced from a given pre-mRNA via use of different poly(A) sites. It has recently been shown that stable mRNA secondary structure can affect the site of polyadenylation of an RNA construct in transfected cells. Klasens et al.,
Nuc. Acids Res.,
1998, 26, 1870-1876. It has also been found that which of multiple polyadenylation sites is used can affect transcript stability. Chu et al.,
J. Immunol.,
1994, 153, 4179-4189. Antisense modulation of mRNA polyadenylation has not previously been reported.
The next step in mRNA processing is splicing of the mRNA, which occurs in the maturation of 90-95% of mammalian mRNAs. Introns (or intervening sequences) are regions of a primary transcript (or the DNA encoding it) that are not included in a finished mRNA. Exons are regions of a primary transcript that remain in the mature mRNA when it reaches the cytoplasm. The exons are “spliced” together to form the mature mRNA sequence. Intron-exon junctions are also referred to as “splice sites” with the 5′ side of the junction often called the “5′ splice site,” or “splice donor site” and the 3′ side the “3′ splice site” or “splice acceptor site.” “Cryptic” splice sites are those which are less often used but may be used when the “usual” splice site is blocked or unavailable.” Alternative splicing, i.e., the use of various combinations of exons, often results in multiple mRNA transcripts from a single gene.
A final step in RNA processing is turnover or degradation of the mRNA. Differential mRNA stabilization is one of several factors in the rate of synthesis of any protein. mRNA degradation rates seem to be related to presence or absence of poly(A) tails and also to the presence of certain sequences in the 3′ end of the mRNA. For example, many mRNAs with short half-lives contain several A(U)
n
A sequences in their 3′-untranslated regions. When a series of AUUUA sequences was inserted into a gene not normally containing them, the half life of the resulting mRNA decreased by 80%. Shaw and Kamen,
Cell,
1986, 46, 659. This may be related to an increase of nucleolytic attack in sequences containing these A(U)
n
A sequences. Other mediators of mRNA stability are also known, such as hormones, translation products (autoregulation/feedback), and low-molecular weight ligands.
Antisense compounds have generally been used to interfere with protein expression, either by interfering directly with translation of the target molecule or, more often, by RNAse-H-mediated degradation of the target mRNA. Antisense interference with 5′ capping of mRNA and prevention of translation factor binding to the mRNA by oligonucleotide masking of the 5′ cap have been disclosed by Baker et al. (WO 91/17755).
Antisense oligonucleotides have been used to modulate splicing, particularly aberrant splicing or splicing of mutant transcripts, often in cell-free reporter systems. A luciferase reporter plasmid system has been used to test the ability of antisense oligonucleotides targeted to the 5′ splice site, 3′ splice site or branchpoint to inhibit splicing of mutated or wild-type adenovirus pre-mRNA sequences in a reporter plasmid. Phosphorothioate oligodeoxynucleotides that can support RNAse H cleavage were found to be better inhibitors of expression of the wild-type adenovirus construct than the 2′-methoxy phosphorothioates that cannot support RNase H, although the reverse was true for oligonucleotides targeted to an adenovirus construct containing human &bgr;-globin splice site sequences. Hodges and Crooke,
Mol. Pharmacol.,
1995, 48, 905-918.
Antisense oligonucleotides have been used to target mutations that lead to aberrant splicing in several genetic diseases. Use of antisense compounds to correct aberrant processing of mutated mRNA sequences is not comprehended by the present invention. Altering, i.e., controlling, the behavior of a cell, particularly the response of a cell to a stimulus, by antisense modulation of “wild-type” or native mRNA processing, the subject of the present invention, has not been described previously.
Phosphorothioate 2′-O-methyl oligoribonucleotides, have been used to target the aberrant 5′ splice site of the mutant &bgr;-globin gene found in patients with &bgr;-thalassemia, a genetic blood disorder. Aberrant splicing of mutant &bgr;-globin mRNA was blocked in vitro in vector constructs containing thalassemic human &bgr;-globin pre-mRNAs using 2′-O-methyl-ribo-oligonucleotides targeted to the branch point sequence in the first intron of the mutant human &bgr;-globin pre mRNAs. 2′-O-methyl oligonucleotides are used because they are stable to RNAses and form stable hybrids with RNA that are not degraded by RNAse H. Dominski and Kole,
Proc. Natl. Acad. Sci.
USA, 1993, 90, 8673-8677. A review article by Kole discusses use of antisense oligonucleotides targeted to aberrant splice sites created by genetic mutations such as &bgr;-thalassemia or cystic fibrosis. It was hypothesized that blocking a splice site with an antisense oligonucleotide will have similar effect to mutation of the splice site, i.e., redirection of splicing. Kole,
Acta Biochimica Polonica,
1997, 44, 231-238. Oligonucleotides targeted to the aberrant &bgr;-globin splice site suppressed aberrant splicing and at least partially restored correct splicing in HeLa cells expressing the mutant transcript. Sierakowska et al., Nucleosides & Nucleotides, 1997, 16,1173-1182; Sierakowska et al.,
Proc. Natl. Acad. Sci.
USA, 1996, 93, 12840-44. U.S. Pat. No. 5,627,274 discloses and WO 94/26887 discloses and claims compositions and methods for combating aberrant splicing in a pre-mRNA molecule containing a mutation, using antisense oligonucleotides which do not activate RNAse H.
Modulation of mutant dystrophin splicing with 2′-O-methyl oligoribonucleotides has been reported both in vitro and in vivo. In dystrophin Kobe, a 52-base pair deletion mutation causes exon 19 to be skipped during splicing. An in vitro minigene splicing system was used to show that a 31-mer 2′-O-methyl oligoribonucleotide complementary to the 5′ half of the deleted sequence in dystrophin Kobe exon 19 inhibited splicing of wild-type pre-mRNA. Takeshima et al.,
J. Clin. Invest.,
1995, 95, 515-520. The same oligonucleotide was used to induce exon skipping from the native dystrophin gene transcript in human cultured lymphoblastoid cells.
Dunckley et al., (
Nucleosides
&
Nucleoti
Baker Brenda F.
Bennett C. Frank
Cooke Stanley T.
Freier Susan M.
Karras James G.
Epps Janet
ISIS Pharmaceuticals Inc.
Law Offices of Jane Massey Licata
Schwartzman Robert A.
LandOfFree
Alteration of cellular behavior by antisense modulation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alteration of cellular behavior by antisense modulation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alteration of cellular behavior by antisense modulation of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2464583